Promoter methylation profile in gallbladder cancer

Roa, Juan Carlos; Anabalón, Leonardo; Roa, Iván; Melo, Angélica; Araya, J. C.; Tapia, O.; Aretxabala, X. De; Muñoz, Sergio; Schneider, Barbara

doi:10.1007/s00535-005-1752-3

Cited by 46 publications

(45 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This value is lower than those from two GC studies in the literature [34,35] . On the other hand, the FHIT hypermethylation frequency was 61.5% in nonneoplastic samples, which is higher than in other studies.…”

Section: Dna Hypermethylation In Gatric Tissuecontrasting

confidence: 60%

“…On the other hand, the FHIT hypermethylation frequency was 61.5% in nonneoplastic samples, which is higher than in other studies. Roa et al [34] reported that FHIT was methylated in 62% of 47 GC samples. Schildhaus et al [35] Figure 2 Methylation status of CDH1, FHIT, MTAP and PLAGL1 promoter in the samples studied.…”

Section: Dna Hypermethylation In Gatric Tissuementioning

confidence: 99%

See 1 more Smart Citation

Promoter hypermethylation ofCDH1,FHIT,MTAPandPLAGL1in gastric adenocarcinoma in individuals from Northern Brazil

Leal

Lima²,

Silva³

et al. 2007

WJG

View full text Add to dashboard Cite

AIM:To evaluate the methylation status of CDH1, FHIT, MTAP and PLAGL1 promoters and the association of these findings with clinico-pathological characteristics. METHODS:Methylation-specific PCR (MSP) assay was performed in 13 nonneoplastic gastric adenocarcinoma, 30 intestinal-type gastric adenocarcinoma and 35 diffusetype gastric adenocarcinoma samples from individuals in Northern Brazil. Statistical analyses were performed using the chi-square or Fisher's exact test to assess associations between methylation status and clinicopathological characteristics. RESULTS:

show abstract

Section: Dna Hypermethylation In Gatric Tissuecontrasting

confidence: 60%

Section: Dna Hypermethylation In Gatric Tissuementioning

confidence: 99%

Promoter hypermethylation ofCDH1,FHIT,MTAPandPLAGL1in gastric adenocarcinoma in individuals from Northern Brazil

Leal

Lima²,

Silva³

et al. 2007

WJG

View full text Add to dashboard Cite

show abstract

“…[37][38][39] Further studies have reported loss of Fhit not due to altered transcript but to promoter hypermethylation of the FHIT gene in breast, gallbladder and NSCL cancers. 36,[40][41][42] On the other hand, we recently showed that downregulation of Fhit protein recently showed that downregulation of Fhit protein levels in the presence of a normal mRNA can occur through Fhit protein posttranslational modification. 43 Our work began based on the observation that Fhit can be phosphorylated by Src on tyrosine 114.…”

Section: E S B I O S C I E N C E D O N O T D I S T R I B U T Ementioning

confidence: 99%

Fhit Expression Protects Against HER2-Driven Breast tumor Development: Unraveling the Molecular Interconnections

et al. 2007

View full text Add to dashboard Cite

“…APC promoter methylation also occurs in a significant number of primary breast tumours (ranging from 28 to 53% of cases, depending on the applied technology) (Jin et al, 2001;Virmani et al, 2001;Liu et al, 2007). The frequency of APC methylation in primary breast tumours increases with tumour stage and size (Virmani et al, 2001;Roa et al, 2004;Chen et al, 2007;Liu et al, 2007). Moreover, hypermethylation of APC can be detected in breast aspirate fluid DNA (Lee et al, 2004) and serum DNA from patients with pre-invasive and early-stage breast cancer (Dulaimi et al, 2004a).…”

mentioning

confidence: 99%

Aberrant methylation of the Adenomatous Polyposis Coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype

et al. 2008

View full text Add to dashboard Cite

Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter occurs in about 40% of breast tumours and has been correlated with reduced APC protein levels. To what extent epigenetic alterations of the APC gene may differ according to specific breast cancer phenotypes, remains to be elucidated. Our aim was to explore the role of APC methylation in the inflammatory breast cancer (IBC) phenotype. The status of APC gene promoter hypermethylation was investigated in DNA from normal breast tissues, IBC and non-IBC by both conventional and real-time quantitative methylation-specific PCR (MSP). APC methylation levels were compared with APC mRNA and protein levels. Hypermethylation of the APC gene promoter was present in 71% of IBC samples (n ¼ 21) and 43% of non-IBC samples (n ¼ 30) by conventional MSP (P ¼ 0.047). The APC gene also showed an increased frequency of high methylation levels in IBC (in 74% of cases, n ¼ 19) vs non-IBC (in 46% of cases, n ¼ 35) using a qMSP assay (P ¼ 0.048). We observed no significant association between APC methylation levels by qMSP and APC mRNA or protein expression levels. In conclusion, for the first time, we report the association of aberrant methylation of the APC gene promoter with the IBC phenotype, which might be of biological and clinical importance.

show abstract

Promoter methylation profile in gallbladder cancer

Cited by 46 publications

References 31 publications

Promoter hypermethylation ofCDH1,FHIT,MTAPandPLAGL1in gastric adenocarcinoma in individuals from Northern Brazil

Promoter hypermethylation ofCDH1,FHIT,MTAPandPLAGL1in gastric adenocarcinoma in individuals from Northern Brazil

Fhit Expression Protects Against HER2-Driven Breast tumor Development: Unraveling the Molecular Interconnections

Aberrant methylation of the Adenomatous Polyposis Coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype

Contact Info

Product

Resources

About